Integrating theory, practice and economics in psychopharmacology

doi:10.1017/CBO9780511544149.015

14 - Integrating theory, practice and economics in psychopharmacology

Published online by Cambridge University Press: 22 August 2009

Jur-Shan Cheng and

Edited by

Chee H. Ng ,

Keh-Ming Lin ,

Bruce S. Singh and

Edmond Y. K. Chiu

Show author details

Keh-Ming Lin: Affiliation:
Division of Mental Health and Substance Abuse Research, National Health Research Institutes, Taiwan
Chun-Yu Chen: Affiliation:
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan
Chia-Hui Chen: Affiliation:
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan
Jur-Shan Cheng: Affiliation:
Center for Health Policy Research and Development, National Health Research Institutes, Taiwan
Sheng-Chang Wang: Affiliation:
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan
Chee H. Ng: Affiliation:
University of Melbourne
Keh-Ming Lin: Affiliation:
National Health Research Institutes, Taiwan
Bruce S. Singh: Affiliation:
University of Melbourne
Edmond Y. K. Chiu: Affiliation:
University of Melbourne

Book contents

Get access

Summary

Critiques and reservations regarding the role and contribution of psychotropic agents in the care of psychiatric patients notwithstanding (Moncrieff, 2001; Healy, 2002), there is little doubt that the advent of modern psychopharmacology in the 1950s has vastly and profoundly altered the landscape of psychiatry. Phenothiazines and related compounds in the past half century have enabled millions of severely mentally ill patients to escape the fate of lifelong confinement. “Antidepressants” and mood stabilizers, equally serendipitously discovered around the same time, often effectively, and at times truly miraculously, lifted millions from various forms of misery. Together they also helped to change (albeit not fast enough and still a long way to go) the public's perception of the mentally ill as well as the professions charged with their care, helping to destigmatize behavioral and emotional problems. Irrespective of the extent of their therapeutic effects, the fact that simple chemical compounds could so profoundly alter behavior was itself inspiring for a new generation of scientists, who helped to usher in a new era of intensive research for the biological substrates of psychiatric phenomena, resulting in the blossoming of biological psychiatry and neuroscience in the last few decades (Carlsson, 1988; Bloom & Kupfer, 1995).

To be sure, examined at closer range, the effect of this “paradigm shift” on the profession and for society is far more complex and nuanced. Advances on the biological front not infrequently have been regarded as threats for our field's expertise in the psychosocial domains.

Type: Chapter
Information: Ethno-psychopharmacology
Advances in Current Practice
, pp. 158 - 168

DOI: https://doi.org/10.1017/CBO9780511544149.015 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aaserud, M., Dahlgren, A. T., Kösters, J. P.et al. (2006). Pharmaceutical policies: effects of ref- erence pricing, other pricing, and purchasing policies.Cochrane Database Syst. Rev., 19(2), CD005979.Google Scholar

Alarcón, R. D., Alegria, M., Bell, C. C.et al. (2002). Chapter 6. Beyond the funhouse mirrors. In D. J. Kupfer, M. B. First and D. A. Regier, eds., A Research Agenda for DSM-V. American Psychiatric Association, 219–81.Google Scholar

Banks, W. A. (2006). The blood–brain barrier in psychoneuroimmunology.Neurol. Clin., 24(3), 413–19.Google Scholar

Block, M. L. & Hong, J. S. (2005). Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism.Prog. Neurobiol., 76(2), 77–98.Google Scholar

Bloom, F. E. & Kupfer, D. J., eds. (1995). Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press.

Cabana, M. D., Rand, C. S., Powe, N. R.et al. (1999). Why don't physicians follow clinical practice guidelines? A framework for improvement.J.A.M.A., 282(15), 1458–65.Google Scholar

Carlsson, A. (1988). The current status of the dopamine hypothesis of schizophrenia.Neuropsychopharmacology, 1(3), 179–86.Google Scholar

Charney, D. S., Barlow, D. H., Botteron, K.et al. (2002). Chapter 2. Neuroscience research agenda to guide development of a pathophysiologically based classification system. In D. J. Kupfer, M. B. First and D. A. Regier, eds., A Research Agenda for DSM-V. American Psychiatric Association, pp. 31–84.Google Scholar

Chen, M.-L. & Chen, C.-H. (2005a). Comparative proteome analysis revealed up-regulation of transthyretin in rat brain under chronic clozapine treatment.J. Psychiatric Res., 41(1/2), 63–8.Google Scholar

Chen, M.-L. & Chen, C.-H. (2005b). Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment.Neuropsychopharmacology, 30(2), 268–77.Google Scholar

Cook, D. & Giacomini, M. (1999). The trials and tribulations of clinical practice guidelines.J.A.M.A., 281(20), 1950–1.Google Scholar

Dantzer, R. (2006). Cytokine, sickness behavior, and depression.Neurol. Clin., 24(3), 441–60.Google Scholar

Dawes, M., Davies, P., Gray, A.et al. (2005). Evidence-Based Practice: A Primer for Health Care Professionals. Edinburgh: ElsevierChurchill Livingstone.

Leon, J. (2006). AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.Expert Rev. Mol. Diagn., 6, 277–86.Google Scholar

Debouck, C. & Goodfellow, P. N. (1999). DNA microarrays in drug discovery and development.Nat. Genet., 21, 48–50.Google Scholar

Domino, E. F. (1999). History of modern psychopharmacology: a personal view with an emphasis on antidepressants.Psychosom. Med., 61(5), 591–8.Google Scholar

Duman, R. S. & Monteggia, L. M. (2006). A neurotrophic model for stress-related mood disorders.Biol. Psychiatry, 59(12), 1116–27.Google Scholar

Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S. & Schulman, K. A. (2005). Implications of pharmacogenomics for drug development and clinical practice.Arch. Intern. Med., 165(20), 2331–6.Google Scholar

Graham, J., Christian, L. & Kiecolt-Glaser, J. (2006). Stress, age, and immune function: toward a lifespan approach.J. Behav. Med., 29, 389–400.Google Scholar

Green, M. F. & Braff, D. L. (2001). Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications.Biol. Psychiatry 49(4), 374–84.Google Scholar

Hallworth, M. J. (2004). The drugs dont work: pharmacogenomics – clinical biochemistry's future?Ann. Clin. Biochem., 41, 260–2.Google Scholar

Healy, D. (2002). The Creation of Psychopharmacology.Cambridge, MA: Harvard University Press.

Hyman, S. E. & Nestler, E. J. (1996). Initiation and adaptation: a paradigm for understanding psychotropic drug action.Am. J. Psychiatry, 153(2), 151–62.Google Scholar

Ishikawa, T., Onishi, Y., Hirano, H.et al. (2004). Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1).Biol. Pharm. Bull., 27, 939–48.Google Scholar

Jadad, A. R. (1998). Randomised Controlled Trials: A User's Guide. London: BMJ Publishing Group.

Kempermann, G. & Kronenberg, G. (2003). Depressed new neurons? Adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression.Biol. Psychiatry, 54(5), 499–503.Google Scholar

Kendler, K. S. (2005). Toward a philosophical structure for psychiatry.Am. J. Psychiatry, 162(3), 433–40.Google Scholar

Kim, S. U. & Vellis, J. (2005). Microglia in health and disease.J. Neurosci. Res., 81(3), 302–13.Google Scholar

Kirchheiner, J., Bertilsson, L., Bruus, H.et al. (2003). Individualized medicine – implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.Pharmacopsychiatry, 36, 235–43.Google Scholar

Kirchheiner, J., Nickchen, K., Bauer, M.et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.Mol. Psychiatry, 9, 442–73.Google Scholar

Kremer, M. (2002). Pharmaceuticals and the developing world.J. Econ. Perspect., 16(4), 67–90.Google Scholar

Landon, M. R. (2005). Ethics and policy perspectives on personalized medicine in the post-genomic era.J. Biolaw Bus., 8(3), 28–36.Google Scholar

Lebowitz, B. D. & Rudorfer, M. V. (1998). Treatment research at the millennium: from efficacy to effectiveness.J. Clin. Psychopharmacol., 18(1), 1.Google Scholar

Lee, H.-J., Cha, J.-H., Ham, B.-J.et al. (2004). Association between a G-protein bold beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders.Pharmacogenomics J., 4, 29–33.Google Scholar

Leonard, B. E. & Myint, A. (2006). Changes in the immune system in depression and dementia: causal or coincidental effects?Dialogues Clin. Neurosc., 8(2), 163–74.Google Scholar

Lieberman, J. A., Stroup, T. S., McEvoy, J. P.et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N. Engl. J. Med., 353(12), 1209–23.Google Scholar

Lin, K.-M. & Lin, M. (2002). Chapter 5. Challenging the Myth of a Culture-free Nosological System. In K. Kurasaki, S. Okazaki and S. Sue, eds., Asian American Mental Health: Assessment Theories and Methods. New York: Plenum, pp. 67–73.

Luhrmann, T. M. (2000). Of Two Minds: The Growing Disorder in American Psychiatry. New York: Knopf.

Malhotra, A. K., Murphy, G. M., Jr. & Kennedy, J. L. (2004). Pharmacogenetics of psychotropic drug response.Am. J. Psychiatry, 161(5), 780–96.Google Scholar

Manji, H. K., Quiroz, J. A., Sporn, J.et al. (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.Biol. Psychiatry, 53(8), 707–42.Google Scholar

Martinelli, C. & Reichhart, J.-M. (2005). Evolution and integration of innate immune systems from fruit flies to man: lessons and questions.J. Endotoxin Res., 11, 243–8.Google Scholar

Matowe, L. & Katerere, D. R. (2002). Globalization and pharmacy: a view from the developing world.Ann. Pharmacother., 36(5), 936–8.Google Scholar

McIntyre, J. S. (2002). Usefulness and limitations of treatment guidelines in psychiatry.World Psychiatry, 1(3), 186–9.Google Scholar

Moncrieff, J. (2001). Are antidepressants overrated? A review of methodological problems in antidepressant trials.J. Nerv. Ment. Dis., 189(5), 288–95.Google Scholar

Müller, N. & Schwarz, M. J. (2006). Neuroimmune endocrine crosstalk in schizophrenia and mood disorders.Expert Rev. Neurother., 6, 1017–38.Google Scholar

NIMH (1998). Bridging Science and Service. A report by the National Advisory Mental Health Council's Clinical Treatment and Services Research Workgroup. Washington, D. C.

NIMH (2001). An Investment in America's Future: Racial/Ethnic Diversity in Mental Health Research Careers. Report of the National Advisory Mental Health Council Workgroup on Racial/Ethnic Diversity in Research Training and Health Disparities Research. Washington, D.C.

NIMH (2005). Treatment Research in Mental Illness: Improving the Nation's Public Mental Health Care through NIMH Funded Interventions Research. Report of the National Advisory Mental Health Council's Workgroup on Clinical Trials. Washington, D. C.

Paul, N. W. & Fangerau, H. (2006). Why should we bother? Ethical and social issues in individualized medicine.Curr. Drug Targets, 7, 1721–7.Google Scholar

Perlis, R. H., Ganz, D. A., Avorn, J.et al. (2005). Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model.J. Clin. Psychopharmacol., 25(5), 427–34.Google Scholar

Rapaport, M. H., Delrahim, K. K., Bresee, C. J.et al. (2005). Celecoxib augmentation of continuously ill patients with schizophrenia.Biol. Psychiatry, 57(12), 1594–6.Google Scholar

Rogers, E. M. (1995). Diffusion of Innovations. New York: Free Press.

Roses, A. D. (2001). Pharmacogenetics.Hum. Mol. Genet., 10, 2261–7.Google Scholar

Rush, A. J., Fava, M., Wisniewski, S. R.et al. (2004). Sequenced treatment alternatives to relieve depression (STAR∗D): rationale and design.Controlled Clinical Trials, 25(1), 119–42.Google Scholar

Russo-Neustadt, A. A. & Chen, M. J. (2005). Brain-derived neurotrophic factor and antidepressant activity.Curr. Pharm. Des., 11, 1495–510.Google Scholar

Schechter, L. E., Ring, R. H., Beyer, C. E.et al. (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies.NeuroRx, 2(4), 590–611.Google Scholar

Serretti, A. & Smeraldi, E. (2004). Neural network analysis in pharmacogenetics of mood disorders.BMC Med. Genet., 5(1), 27.Google Scholar

Serretti, A., Cusin, C., Rossini, D.et al. (2004). Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.Am. J. Med. Genet. B Neuropsychiatr. Genet., 129B(1), 36–40.Google Scholar

Serretti, A., Benedetti, F., Zanardi, R. & Smeraldi, E. (2005). The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments.Prog. Neuro psychopharmacol. Biol. Psychiatry, 29(6), 1074–84.Google Scholar

Stahl, S. M. (2006). Finding what you are not looking for: strategies for developing novel treatments in psychiatry.NeuroRx, 3(1), 3–9.Google Scholar

Tucker, G. (2004). Pharmacogenetics – expectations and reality.B.M.J. 329(7456), 4–6.Google Scholar

Weinshilboum, R. & Wang, L. (2004). Pharmacogenomics: bench to bedside.Nat Rev. Drug Discov., 3(9), 739–48.Google Scholar

Wells, K. B. (1999). Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research.Am. J. Psychiatry, 156(1), 5–10.Google Scholar

Yoshida, K., Takahashi, H., Higuchi, H.et al. (2004). Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.Am. J. Psychiatry, 161(9), 1575–80.Google Scholar

Ziv, Y., Ron, N., Butovsky, O.et al. (2006). Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood.Nat. Neurosci., 9(2), 268–75.Google Scholar

Book contents

14 - Integrating theory, practice and economics in psychopharmacology

Summary

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive